EP0767167B1 - Trifluoromethylsulfonylphenyl or trifluoromethylsulfinylphenyl group containing 2-cyano-3-hydroxy-propenamide derivatives, process for their preparation, their use as medicaments and pharmaceutical compositions containing them - Google Patents

Trifluoromethylsulfonylphenyl or trifluoromethylsulfinylphenyl group containing 2-cyano-3-hydroxy-propenamide derivatives, process for their preparation, their use as medicaments and pharmaceutical compositions containing them Download PDF

Info

Publication number
EP0767167B1
EP0767167B1 EP96402091A EP96402091A EP0767167B1 EP 0767167 B1 EP0767167 B1 EP 0767167B1 EP 96402091 A EP96402091 A EP 96402091A EP 96402091 A EP96402091 A EP 96402091A EP 0767167 B1 EP0767167 B1 EP 0767167B1
Authority
EP
European Patent Office
Prior art keywords
formula
compound
compounds
group
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP96402091A
Other languages
German (de)
French (fr)
Other versions
EP0767167A1 (en
Inventor
David Paul Kay
Elizabert Anne Kuo
Richard Alexander Williamson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Hoechst Marion Roussel
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel, Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel
Publication of EP0767167A1 publication Critical patent/EP0767167A1/en
Application granted granted Critical
Publication of EP0767167B1 publication Critical patent/EP0767167B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/40—Y being a hydrogen or a carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Definitions

  • the present invention relates to novel 2-cyano-3-hydroxy-propenamides containing a trifluoromethylsulfonylphenyl group or special trifluoromethyl-sulfinylphenyl, their preparation processes, the compositions pharmaceuticals containing them and their use as medication.
  • the preferred compounds according to the invention include those in which R 1 represents a cyclopropyl group and R 2 , R 3 and m are as defined above.
  • R 3 represents a hydrogen atom or a methyl group, quite preferably a hydrogen atom and R 1 , R 2 and m are such that defined above.
  • R 3 represents a hydrogen atom or a methyl group
  • R 2 represents a group -S (O) n - (CF 2 ) x CF 3
  • R 1 represents a cyclopropyl group and m denotes zero and in which n denotes 1 or 2 and x denotes zero.
  • the compounds of formula (I) are of an acidic nature.
  • the base addition salts of the compounds of formula (I) can be advantageously prepared by reacting, in approximately stoichiometric proportions, a base mineral or organic with the compound of formula (I).
  • the salts can be prepared without intermediate isolation of corresponding acid compound.
  • the compounds according to the invention have properties very interesting pharmacologicals. Of particular interest is their remarkable anti-inflammatory activity. They both inhibit the inflammatory response caused by irritants, and delayed hypersensitivity reactions by interfering with the activation of immune cells by a particular antigen.
  • the invention also relates to a process for the preparation of compounds of formula I as defined above, comprising the reaction of a compound of formula (IV) in which R 2 , R 3 , m, n and x are as defined above, successively with a base, e.g. sodium hydride or lithium diisopropylamide, where appropriate in the presence of a catalyst such as imidazole, then with a compound of formula (V) X-CO-R 1 in which X represents a labile group, e.g. a halogen atom, and R 1 is as defined above.
  • the compound of formula I thus obtained can then be isolated and / or (if desired) transformed into a salt.
  • the compounds of formula IV can for example be prepared by the oxidation of the sulfur atom of a compound of formula (IVa) in which R ' 2 denotes a group -S- (CF 2 ) x -CF 3 and R 3 , x and m are as defined above.
  • the compounds of formula (IVa) as defined above can for example be prepared by the reaction of a compound of formula (IIa) wherein R ' 2 , x, R 3 and m are as defined above, with a compound of formula III or a functional derivative thereof.
  • the compounds of formula (IV) can also be prepared by first oxidizing the sulfur atom of compounds of formula (IIa) (as defined above) followed by reaction of the product with a compound of formula (III) (such as defined above) or a derivative thereof.
  • the reaction of the compounds of formula (IIa) and (III) is carried out in the presence of diisopropylcarbodiimide or dicyclohexylcarbodiimide in an anhydrous organic solvent such as dichloromethane or tetrahydrofuran.
  • the functional derivative of the acid of formula (III) is preferably cyanoacetyl chloride prepared in situ from phosphorus pentachloride and cyanoacetic acid (see J. Med. Chem., 1985, 28 , 559-568 ).
  • the oxidation of the compounds of formula (IVa) can be carried out using known oxidizing agents such as for example peracetic acid.
  • the trifluoromethylthio group can be oxidized to a sulfinyl or sulfonyl group.
  • reaction of the compound of formula (IV) with hydride of sodium is preferably carried out in an organic solvent anhydrous such as tetrahydrofuran.
  • reaction with a compound of formula (V) is also preferably carried out in an anhydrous organic solvent such as tetrahydrofuran.
  • R 1 represents a cyclopropyl group.
  • R 3 represents a hydrogen atom or a methyl group, preferably a hydrogen atom.
  • R 3 represents a hydrogen atom or a methyl group
  • R 2 represents a group -S (O) n - (CF 2 ) x CF 3 and m denotes zero, n denotes 1 or 2 and x denotes zero.
  • Medicines comprising a compound of formula I under salt form of it are useful, for example, in the treatment of rheumatoid arthritis, inflammatory diseases immune or non-immune (e.g. graft versus host reaction disease, transplant reactions, uveitis) and cancer.
  • inflammatory diseases immune or non-immune e.g. graft versus host reaction disease, transplant reactions, uveitis
  • cancer e.g. graft versus host reaction disease, transplant reactions, uveitis
  • Immunosuppressive effects of new compounds can for example be highlighted by the dosage of the enzyme dihydro-orotate dehydrogenase.
  • DHO-DH Dihydro-orotate dehydrogenase catalyzes the fourth step in the de novo biosynthesis of pyrimidine. Its inhibition would lead to the exhaustion of nucleotides pyrimidines and therefore inhibition of synthesis of DNA and RNA and cell proliferation. Pyrimidines are also necessary for glycosylation lipids and proteins. Cell proliferation is a critical component of the immune response, during which the immune cells have a large need for nucleotides. A DHO-DH inhibitor would thus a potential immunosuppressive agent and, in addition, would have potential therapeutic benefits in disorders involving aberrant cell proliferation.
  • the usual dose of new products to be administered varies depending on the compound used, the patient being treated and the disease in question and can be for example from 0.1 mg to 2000 mg, preferably 0.5 to 200 mg per day orally.
  • compositions comprising, as a principle active, at least one compound of formula (I) as defined above or a pharmaceutically acceptable base addition salt of it in association with one or more pharmacologically diluents, carriers and / or excipients acceptable.
  • the compounds of formula (I) and their base addition salts can by example be incorporated into pharmaceutical compositions intended for oral, rectal or parenteral.
  • compositions can for example be solid or liquid and can be in forms conventionally used in human medicine, such that: naked or coated tablets, capsules, capsules, granules, suppositories, solutions, by ex. for injection; they can be prepared according to classical methods.
  • the active ingredient (s) can be formulated in pharmaceutical compositions with excipients conventionally used in the compositions pharmaceuticals such as talc, gum arabic, lactose, starch, magnesium stearate, butter cocoa, aqueous or non-aqueous vehicles, fats of animal or vegetable origin, paraffinic derivatives, glycols, various wetting agents, dispersants or emulsifiers and the Conservatives.
  • excipients such as talc, gum arabic, lactose, starch, magnesium stearate, butter cocoa, aqueous or non-aqueous vehicles, fats of animal or vegetable origin, paraffinic derivatives, glycols, various wetting agents, dispersants or emulsifiers and the Conservatives.
  • a method of treatment of rheumatoid arthritis, diseases chronic inflammatory of immune or non-immune origin or cancer in a human or animal subject including administration about an effective amount of a compound of formula (I) as defined above or a salt pharmacologically acceptable base addition thereof.
  • Example 1 Preparation of N- (4'-trifluoromethylsulfinylphenyl) cyanoacetamide and N- (4'-trifluoromethylsulfonylphenyl) cyanoacetamide.
  • N- (4'-trifluoromethylsulfinylphenyl) cyanoacetamide (3.1 g, 0.0112 mol) in dry THF (100 ml) was treated with imidazole (10 mg, catalytic) and sodium hydride ( 80% oil dispersion) (0.75 g, 0.0246 mol) and stirred at room temperature for 90 minutes.
  • Cyclopropylcarbonyl chloride (1.32 ml, 0.0146 mol) was added dropwise and the solution stirred at room temperature for 10 minutes, poured into ice / 1M HCl and filtered.
  • N- (4'-trifluoromethylsulfonylphenyl) cyanoacetamide by the above method gave N- (4'-trifluoromethylsulfinylphenyl) 2-cyano-3-cyclopropyl-3-hydroxy-prop-2-enamide (65%) : M 168-170 Ā°;
  • the transformation of dihydro-orotate into orotate catalyzed by DHO-DH of the human spleen membrane is carried out by the reduction of coenzyme Q 10 .
  • the reoxidation of coenzyme Q 10 is linked to the reduction of dichlorophenolindophenol and is followed by the loss of absorbance at 650 nm.
  • the rate of loss of absorbance is a direct measure of the reaction catalyzed by the enzyme DHO-DH.
  • the reaction rates were measured in the presence of a range of concentrations of the test compound and the concentration giving 50% inhibition (IC 50 ) was determined using the graphs (see Williamson et al.
  • the splenic tissue was cut, then homogenized with a Teflon glass homogenizer (approximately 10 passages 250 rpm) in 10 volumes of homogenization buffers (10 mM Tris-HCl containing 0.25 M sucrose, 10 ā‡ g / ml soybean trypsin inhibitor, 2 ā‡ g / ml aprotinin, pepstatin A and leupeptin pH 7.4.
  • the homogenate was centrifuged at ā‡ 470 g for 10 minutes and the supernatant preserved.
  • the pellets were resuspended in 4-6 volumes of homogenization buffer using 5 passages of the Teflon glass homogenizer (250 rpm) and centrifuged for 10 minutes at ā‡ 470 g.
  • the supernatant has been collected with that from the first centrifugation step (post-nuclear fraction); the pellets containing the nuclei and tissue debris was discarded.
  • the post-nuclear supernatant was centrifuged at 125,000 xg for 40 minutes.
  • the pellets were resuspended in homogenization buffer (2 ml / g of wet tissue) using approximately 10 passages of the homogenizer in Teflon glass. Aliquots of the preparation were stored at -80 Ā° C.
  • Membranes have not been re-frozen once thawed (see Ozols J. "Preparation of Membrane Fractions" Membrane Fractions], in: Methods in Enzymology Volume 182, Guide to Protein Purification (Ed. Deutscher MP), pp 225-235. Academic Press, London, 1990).

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Trifluoromethyl -sulphonyl or -sulphinyl phenyl 2-cyano-3-hydroxy propenamide derivs. of formula (I) and their salts are new. R1 = cyclopropyl or CH2CH=CH2; R2 = S(O)n(CF2)xCF3; n = 1 or 2; x = 0 or 1; R3 = H or 1-3C alkyl, m = 0 or 1. Also claimed are the intermediates of formula (IV).

Description

La prƩsente invention concerne des nouveaux 2-cyano-3-hydroxy-propƩnamides contenant un groupe trifluoromƩthylsulfonylphƩnyle ou trifluoromƩthyl-sulfinylphƩnyle spƩcial, leurs procƩdƩs de prƩparation, les compositions pharmaceutiques les contenant et leur utilisation comme mƩdicaments.The present invention relates to novel 2-cyano-3-hydroxy-propenamides containing a trifluoromethylsulfonylphenyl group or special trifluoromethyl-sulfinylphenyl, their preparation processes, the compositions pharmaceuticals containing them and their use as medication.

On connaĆ­t de EP-B 484223, EP-A 533573, EP-A 551230, EP-A 606175 et DE-A 2555789 certains composĆ©s contenant une structure de 2-cyano-3-hydroxy-propĆ©namide; toutefois, ces composĆ©s sont diffĆ©rents en structure et ne prĆ©sentent pas la mĆŖme puissance inattendue vis-Ć -vis des enzymes humains pertinents que les nouveaux composĆ©s de la prĆ©sente invention.We know from EP-B 484223, EP-A 533573, EP-A 551230, EP-A 606175 and DE-A 2555789 certain compounds containing a 2-cyano-3-hydroxy-propenamide structure; however, these compounds are different in structure and do not exhibit the same unexpected power against human enzymes relevant as the new compounds of this invention.

Selon un aspect de l'invention, on fournit des composƩs de formule (I) :

Figure 00010001
dans laquelle

R1
reprƩsente un groupement cyclopropyle ou un groupement -CH2-CH = CH2;
R2
reprƩsente un groupement -S(O)n-(CF2)x-CF3, dans lequel
n
dƩsigne 1 ou 2, et x dƩsigne zƩro ou 1;
R3
reprĆ©sente un atome d'hydrogĆØne ou un radical alkyle contenant de 1 Ć  3 atomes de carbone; et
m
dƩsigne zƩro ou 1;
ainsi que leurs sels pharmaceutiquement acceptables.According to one aspect of the invention, compounds of formula (I) are provided:
Figure 00010001
in which
R 1
represents a cyclopropyl group or a group -CH 2 -CH = CH 2 ;
R 2
represents a group -S (O) n - (CF 2 ) x -CF 3 , in which
not
denotes 1 or 2, and x denotes zero or 1;
R 3
represents a hydrogen atom or an alkyl radical containing from 1 to 3 carbon atoms; and
m
denotes zero or 1;
as well as their pharmaceutically acceptable salts.

Les composƩs prƩfƩrƩs selon l'invention incluent ceux dans lesquels R1 reprƩsente un groupement cyclopropyle et R2, R3 et m sont tels que dƩfinis ci-dessus. The preferred compounds according to the invention include those in which R 1 represents a cyclopropyl group and R 2 , R 3 and m are as defined above.

D'autres composĆ©s prĆ©fĆ©rĆ©s selon l'invention incluent ceux dans lesquels R3 reprĆ©sente un atome d'hydrogĆØne ou un groupement mĆ©thyle, de faƧon tout-Ć -fait prĆ©fĆ©rentielle un atome d'hydrogĆØne et R1, R2 et m sont tels que dĆ©finis ci-dessus.Other preferred compounds according to the invention include those in which R 3 represents a hydrogen atom or a methyl group, quite preferably a hydrogen atom and R 1 , R 2 and m are such that defined above.

Les composĆ©s particuliĆØrement prĆ©fĆ©rĆ©s selon l'invention sont ceux dans lesquels R3 reprĆ©sente un atome d'hydrogĆØne ou un groupement mĆ©thyle; R2 reprĆ©sente un groupement -S(O)n-(CF2)xCF3, R1 reprĆ©sente un groupement cyclopropyle et m dĆ©signe zĆ©ro et dans lesquels n dĆ©signe 1 ou 2 et x dĆ©signe zĆ©ro.The particularly preferred compounds according to the invention are those in which R 3 represents a hydrogen atom or a methyl group; R 2 represents a group -S (O) n - (CF 2 ) x CF 3 , R 1 represents a cyclopropyl group and m denotes zero and in which n denotes 1 or 2 and x denotes zero.

Les composĆ©s particuliĆØrement prĆ©fĆ©rĆ©s selon l'invention sont:

  • le N-(4'-trifluoromĆ©thylsulfinylphĆ©nyl)2-cyano-3-cyclopropyl-3-hydroxy-prop-2-Ć©namide
  • le N-(4'-trifluoromĆ©thylsulfonylphĆ©nyl)2-cyano-3-cyclopropyl-3-hydroxy-prop-2-Ć©namide
    • The particularly preferred compounds according to the invention are:
  • N- (4'-trifluoromethylsulfinylphenyl) 2-cyano-3-cyclopropyl-3-hydroxy-prop-2-enamide
  • N- (4'-trifluoromethylsulfonylphenyl) 2-cyano-3-cyclopropyl-3-hydroxy-prop-2-enamide

    • Les composĆ©s de formule (I) sont de nature acide. Les sels d'addition de base des composĆ©s de formule (I) peuvent ĆŖtre prĆ©parĆ©s de maniĆØre avantageuse en faisant rĆ©agir, dans des proportions approximativement stoechiomĆ©triques, une base minĆ©rale ou organique avec le composĆ© de formule (I). Les sels peuvent ĆŖtre prĆ©parĆ©s sans isolement intermĆ©diaire du composĆ© acide correspondant.The compounds of formula (I) are of an acidic nature. The base addition salts of the compounds of formula (I) can be advantageously prepared by reacting, in approximately stoichiometric proportions, a base mineral or organic with the compound of formula (I). The salts can be prepared without intermediate isolation of corresponding acid compound.

    Les composĆ©s selon l'invention prĆ©sentent des propriĆ©tĆ©s pharmacologiques trĆØs intĆ©ressantes. D'un intĆ©rĆŖt particulier est leur activitĆ© anti-inflammatoire remarquable. Ils inhibent Ć  la fois la rĆ©ponse inflammatoire provoquĆ©e par des agents irritants, et les rĆ©actions d'hypersensibilitĆ© retardĆ©es en gĆŖnant l'activation des cellules immunitaires par un antigĆØne particulier.The compounds according to the invention have properties very interesting pharmacologicals. Of particular interest is their remarkable anti-inflammatory activity. They both inhibit the inflammatory response caused by irritants, and delayed hypersensitivity reactions by interfering with the activation of immune cells by a particular antigen.

    L'invention concerne Ʃgalement un procƩdƩ de prƩparation de composƩs de formule I tel que dƩfinis ci-dessus, comprenant la rƩaction d'un composƩ de formule (IV)

    Figure 00020001
    dans laquelle R2, R3, m, n et x sont tels que dĆ©finis ci-dessus, successivement avec une base, par ex. l'hydrure de sodium ou le diisopropylamide de lithium, le cas Ć©chĆ©ant en prĆ©sence d'un catalyseur tel que l'imidazole, puis avec un composĆ© de formule (V) X-CO-R1 dans laquelle X reprĆ©sente un groupement labile, par ex. un atome d'halogĆØne, et R1 est tel que dĆ©fini ci-dessus. Le composĆ© de formule I ainsi obtenu peut alors ĆŖtre isolĆ© et/ou (si on le souhaite) transformĆ© en un sel.The invention also relates to a process for the preparation of compounds of formula I as defined above, comprising the reaction of a compound of formula (IV)
    Figure 00020001
    in which R 2 , R 3 , m, n and x are as defined above, successively with a base, e.g. sodium hydride or lithium diisopropylamide, where appropriate in the presence of a catalyst such as imidazole, then with a compound of formula (V) X-CO-R 1 in which X represents a labile group, e.g. a halogen atom, and R 1 is as defined above. The compound of formula I thus obtained can then be isolated and / or (if desired) transformed into a salt.

    Les composĆ©s de formule IV peuvent par exemple ĆŖtre prĆ©parĆ©s par l'oxydation de l'atome de soufre d'un composĆ© de formule (IVa)

    Figure 00030001
    dans laquelle R'2 dƩsigne un groupement -S-(CF2)x-CF3 et R3, x et m sont tels que dƩfinis ci-dessus.The compounds of formula IV can for example be prepared by the oxidation of the sulfur atom of a compound of formula (IVa)
    Figure 00030001
    in which R ' 2 denotes a group -S- (CF 2 ) x -CF 3 and R 3 , x and m are as defined above.

    Les composĆ©s de formule (IVa) tels que dĆ©finis ci-dessus peuvent par exemple ĆŖtre prĆ©parĆ©s par la rĆ©action d'un composĆ© de formule (IIa)

    Figure 00030002
    dans laquelle R'2, x, R3 et m sont tels que dƩfinis ci-dessus, avec un composƩ de formule III ou un dƩrivƩ fonctionnel de celui-ci.
    Figure 00030003
    The compounds of formula (IVa) as defined above can for example be prepared by the reaction of a compound of formula (IIa)
    Figure 00030002
    wherein R ' 2 , x, R 3 and m are as defined above, with a compound of formula III or a functional derivative thereof.
    Figure 00030003

    Les composĆ©s de formule (IV) peuvent ĆŖtre Ć©galement prĆ©parĆ©s en oxydant d'abord l'atome de soufre de composĆ©s de formule (IIa) (tel que dĆ©finis ci-dessus) suivi de la rĆ©action du produit avec un composĆ© de formule (III) (tel que dĆ©fini ci-dessus) ou un dĆ©rivĆ© de celui-ci.The compounds of formula (IV) can also be prepared by first oxidizing the sulfur atom of compounds of formula (IIa) (as defined above) followed by reaction of the product with a compound of formula (III) (such as defined above) or a derivative thereof.

    De prĆ©fĆ©rence, la rĆ©action des composĆ©s de formule (IIa) et (III) est effectuĆ©e en prĆ©sence de diisopropylcarbodiimide ou de dicyclohexylcarbodiimide dans un solvant organique anhydre tel que le dichloromĆ©thane ou le tĆ©trahydrofuranne. Le dĆ©rivĆ© fonctionnel de l'acide de formule (III) est de prĆ©fĆ©rence le chlorure de cyanoacĆ©tyle prĆ©parĆ© in situ Ć  partir du pentachlorure de phosphore et de l'acide cyanoacĆ©tique (voir J. Med. Chem., 1985, 28, 559-568). L'oxydation des composĆ©s de formule (IVa) peut ĆŖtre effectuĆ©e en utilisant des agents d'oxydation connus tels que par exemple l'acide peracĆ©tique. Selon les conditions rĆ©actionnelles (par ex. la tempĆ©rature, le solvant, le temps de rĆ©action), le groupement trifluoromĆ©thylthio peut ĆŖtre oxidĆ© en groupement sulfinyle ou sulfonyle.Preferably, the reaction of the compounds of formula (IIa) and (III) is carried out in the presence of diisopropylcarbodiimide or dicyclohexylcarbodiimide in an anhydrous organic solvent such as dichloromethane or tetrahydrofuran. The functional derivative of the acid of formula (III) is preferably cyanoacetyl chloride prepared in situ from phosphorus pentachloride and cyanoacetic acid (see J. Med. Chem., 1985, 28 , 559-568 ). The oxidation of the compounds of formula (IVa) can be carried out using known oxidizing agents such as for example peracetic acid. Depending on the reaction conditions (eg temperature, solvent, reaction time), the trifluoromethylthio group can be oxidized to a sulfinyl or sulfonyl group.

    La rƩaction du composƩ de formule (IV) avec l'hydrure de sodium est de prƩfƩrence effectuƩe dans un solvant organique anhydre tel que le tƩtrahydrofuranne. La rƩaction avec un composƩ de formule (V) est Ʃgalement effectuƩe de prƩfƩrence dans un solvant organique anhydre tel que le tƩtrahydrofuranne.The reaction of the compound of formula (IV) with hydride of sodium is preferably carried out in an organic solvent anhydrous such as tetrahydrofuran. The reaction with a compound of formula (V) is also preferably carried out in an anhydrous organic solvent such as tetrahydrofuran.

    Les composƩs de formule IV

    Figure 00040001
    dans laquelle

  • R2 reprĆ©sente un groupement : -S(O)n-(CF2)x-CF3; dans lequel n dĆ©signe 1 ou 2 et x est zĆ©ro ou 1;
  • R3 reprĆ©sente un atome d'hydrogĆØne ou un radical alkyle contenant de 1 Ć  3 atomes de carbone; et m dĆ©signe zĆ©ro ou 1, sont des nouveaux composĆ©s et ils constituent une autre disposition de la prĆ©sente invention.
    • The compounds of formula IV
    Figure 00040001
    in which
  • R 2 represents a group: -S (O) n - (CF 2 ) x -CF 3 ; wherein n denotes 1 or 2 and x is zero or 1;
  • R 3 represents a hydrogen atom or an alkyl radical containing from 1 to 3 carbon atoms; and m denotes zero or 1, are new compounds and constitute another provision of the present invention.

    • Les composĆ©s de formule (I) et les sels d'addition de base de ceux-ci trouvent une utilisation comme mĆ©dicaments.The compounds of formula (I) and the addition salts of basis of these find use as drugs.

    Selon un autre aspect de l'invention, on prƩvoit l'utilisation, comme mƩdicaments, des composƩs de formule (I) tels que dƩfinis ci-dessus et les sels d'addition de base pharmacologiquement acceptables de ceux-ci.According to another aspect of the invention, provision is made for the use, as medicaments, compounds of formula (I) such as defined above and the base addition salts pharmacologically acceptable of these.

    On prĆ©fĆØre utiliser comme mĆ©dicament les composĆ©s selon l'invention dans lesquels R1 reprĆ©sente un groupement cyclopropyle.It is preferred to use as medicament the compounds according to the invention in which R 1 represents a cyclopropyl group.

    On prĆ©fĆØre Ć©galement utiliser comme mĆ©dicaments les composĆ©s selon l'invention dans lesquels R3 reprĆ©sente un atome d'hydrogĆØne ou un groupement mĆ©thyle, de prĆ©fĆ©rence un atome d'hydrogĆØne.It is also preferred to use as medicaments the compounds according to the invention in which R 3 represents a hydrogen atom or a methyl group, preferably a hydrogen atom.

    Les composĆ©s particuliĆØrement prĆ©fĆ©rĆ©s selon l'invention pour une utilisation comme mĆ©dicaments sont ceux dans lesquels R3 reprĆ©sente un atome d'hydrogĆØne ou un groupement mĆ©thyle; R2 reprĆ©sente un groupement -S(O)n-(CF2)xCF3 et m dĆ©signe zĆ©ro, n dĆ©signe 1 ou 2 et x dĆ©signe zĆ©ro.The particularly preferred compounds according to the invention for use as medicaments are those in which R 3 represents a hydrogen atom or a methyl group; R 2 represents a group -S (O) n - (CF 2 ) x CF 3 and m denotes zero, n denotes 1 or 2 and x denotes zero.

    Comme mĆ©dicaments, on prĆ©fĆØre notamment utiliser les composĆ©s suivants :

  • le N-(4'-trifluoromĆ©thylsulfinylphĆ©nyl)2-cyano-3-cyclopropyl-3-hydroxy-prop-2-Ć©namide
  • N-(4'-trifluoromĆ©thylsulfonylphĆ©nyl)2-cyano-3-cyclopropyl-3-hydroxy-prop-2-Ć©namide.
    • As medicaments, it is particularly preferred to use the following compounds:
  • N- (4'-trifluoromethylsulfinylphenyl) 2-cyano-3-cyclopropyl-3-hydroxy-prop-2-enamide
  • N- (4'-trifluoromethylsulfonylphenyl) 2-cyano-3-cyclopropyl-3-hydroxy-prop-2-enamide.

    • Les mĆ©dicaments comprenant un composĆ© de formule I sous forme d'un sel de celui-ci sont utiles, par exemple, dans le traitement de polyarthrite rhumatoĆÆde, des maladies inflammatoires chroniques d'origine immunitaires ou non-immunitaires (par ex. maladie de rĆ©action du greffon contre l'hĆ“te, les rĆ©actions de transplantation, uvĆ©ite) et du cancer.Medicines comprising a compound of formula I under salt form of it are useful, for example, in the treatment of rheumatoid arthritis, inflammatory diseases immune or non-immune (e.g. graft versus host reaction disease, transplant reactions, uveitis) and cancer.

    Les effets immunosuppresseurs des nouveaux composĆ©s peuvent par exemple ĆŖtre mis en Ć©vidence par le dosage de l'enzyme dihydro-orotate dĆ©shydrogĆ©nase.Immunosuppressive effects of new compounds can for example be highlighted by the dosage of the enzyme dihydro-orotate dehydrogenase.

    La dihydro-orotate dĆ©shydrogĆ©nase (DHO-DH) catalyse la quatriĆØme Ć©tape dans la biosynthĆØse de novo de la pyrimidine. Son inhibition conduirait Ć  l'Ć©puisement des nuclĆ©otides pyrimidiniques et par consĆ©quent Ć  une inhibition de la synthĆØse d'ADN et d'ARN et de la prolifĆ©ration cellulaire. Les pyrimidines sont Ć©galement nĆ©cessaires pour la glycosylation des lipides et des protĆ©ines. La prolifĆ©ration cellulaire est un composant critique de la rĆ©ponse immunitaire, au cours de laquelle les cellules immunitaires ont un grand besoin en nuclĆ©otides. Un inhibiteur de la DHO-DH serait ainsi un agent immunosuppresseur potentiel et, en outre, aurait des bĆ©nĆ©fices thĆ©rapeutiques potentiels dans des troubles impliquant une prolifĆ©ration cellulaire aberrante.Dihydro-orotate dehydrogenase (DHO-DH) catalyzes the fourth step in the de novo biosynthesis of pyrimidine. Its inhibition would lead to the exhaustion of nucleotides pyrimidines and therefore inhibition of synthesis of DNA and RNA and cell proliferation. Pyrimidines are also necessary for glycosylation lipids and proteins. Cell proliferation is a critical component of the immune response, during which the immune cells have a large need for nucleotides. A DHO-DH inhibitor would thus a potential immunosuppressive agent and, in addition, would have potential therapeutic benefits in disorders involving aberrant cell proliferation.

    La dose habituelle des nouveaux produits Ć  administrer varie selon le composĆ© utilisĆ©, le patient traitĆ© et la maladie en question et peut ĆŖtre par exemple de 0,1 mg Ć  2000 mg, de prĆ©fĆ©rence de 0,5 Ć  200 mg par jour par voie orale.The usual dose of new products to be administered varies depending on the compound used, the patient being treated and the disease in question and can be for example from 0.1 mg to 2000 mg, preferably 0.5 to 200 mg per day orally.

    Selon un autre aspect de l'invention, on fournit des compositions pharmacologiques comprenant, Ơ titre de principe actif, au moins un composƩ de formule (I) tel que dƩfini ci-dessus ou un sel d'addition de base pharmaceutiquement acceptable de celui-ci en association avec un ou plusieurs diluants, supports et/ou excipients pharmacologiquement acceptables.According to another aspect of the invention, there are provided pharmacological compositions comprising, as a principle active, at least one compound of formula (I) as defined above or a pharmaceutically acceptable base addition salt of it in association with one or more pharmacologically diluents, carriers and / or excipients acceptable.

    Pour une utilisation comme mĆ©dicaments, les composĆ©s de formule (I) et leurs sels d'addition de base peuvent par exemple ĆŖtre incorporĆ©s dans des compositions pharmaceutiques destinĆ©es Ć  l'administration par voie orale, rectale ou parentĆ©rale.For use as drugs, the compounds of formula (I) and their base addition salts can by example be incorporated into pharmaceutical compositions intended for oral, rectal or parenteral.

    Ces compositions pharmaceutiques peuvent par exemple ĆŖtre solides ou liquides et peuvent ĆŖtre sous des formes utilisĆ©es de maniĆØre classique en mĆ©dicine humaine, telles que : les comprimĆ©s nus ou enrobĆ©s, les capsules, les gelules, les granulĆ©s, les suppositoires, les solutions, par ex. pour injection; elles peuvent ĆŖtre prĆ©parĆ©es selon des mĆ©thodes classiques.These pharmaceutical compositions can for example be solid or liquid and can be in forms conventionally used in human medicine, such that: naked or coated tablets, capsules, capsules, granules, suppositories, solutions, by ex. for injection; they can be prepared according to classical methods.

    Le(s) principe(s) actif(s) peut (peuvent) ĆŖtre formulĆ©(s) en compositions pharmaceutiques avec les excipients utilisĆ©s de maniĆØre classique dans les compositions pharmaceutiques telles que le talc, la gomme arabique, le lactose, l'amidon, le stĆ©arate de magnĆ©sium, le beurre de cacao, les vĆ©hicules aqueux ou non-aqueux, les matiĆØres gras d'origine animale ou vĆ©gĆ©tale, les dĆ©rivĆ©s paraffiniques, les glycols, divers agent mouillants, dispersants ou Ć©mulsionnants et les conservateurs.The active ingredient (s) can be formulated in pharmaceutical compositions with excipients conventionally used in the compositions pharmaceuticals such as talc, gum arabic, lactose, starch, magnesium stearate, butter cocoa, aqueous or non-aqueous vehicles, fats of animal or vegetable origin, paraffinic derivatives, glycols, various wetting agents, dispersants or emulsifiers and the Conservatives.

    Selon un autre aspect de l'invention, on fournit une mĆ©thode de traitement de polyarthrite rhumatoĆÆde, de maladies inflammatoires chroniques d'origine immunitaire ou non-immunitaire ou de cancer chez un sujet humain ou animal, comprenant l'administration au sujet d'une quantitĆ© efficace d'un composĆ© de formule (I) tel que dĆ©fini ci-dessus ou un sel d'addition de base pharmacologiquement acceptable de celui-ci.According to another aspect of the invention, a method of treatment of rheumatoid arthritis, diseases chronic inflammatory of immune or non-immune origin or cancer in a human or animal subject, including administration about an effective amount of a compound of formula (I) as defined above or a salt pharmacologically acceptable base addition thereof.

    L'invention est encore illustrƩe par les exemples non-limitants suivants :The invention is further illustrated by the non-limiting examples following:

    Exemple 1 : PrƩparation de N-(4'-trifluoromƩthylsulfinylphƩnyl)cyanoacƩtamide et de N-(4'-trifluoromƩthylsulfonylphƩnyl)cyanoacƩtamide. Example 1 : Preparation of N- (4'-trifluoromethylsulfinylphenyl) cyanoacetamide and N- (4'-trifluoromethylsulfonylphenyl) cyanoacetamide.

  • A) Le N-(4'-trifluoromĆ©thylthiophĆ©nyl)cyanoacĆ©tamide (4,35 g, 0,0167 mol) (EP 0484223) dans de l'acide acĆ©tique (15 ml) a Ć©tĆ© agitĆ© Ć  tempĆ©rature ambiante pendant une nuit avec de l'acide peracĆ©tique (8,0 ml de 32% p/v, 0,035 mol). Le mĆ©lange a Ć©tĆ© versĆ© sur de la glace/eau et extrait dans de l'acĆ©tate d'Ć©thyle. Les extraits ont Ć©tĆ© lavĆ©s par une solution aqueuse de bicarbonate de sodium, sĆ©chĆ©s (MgSO4) et Ć©vaporĆ©s pour donner un solide incolore (4,6 g). La chromotographie sur gel de silice (1-10% d'acĆ©tone dans du dichloromĆ©thane) a donnĆ© le N-(4'-trifluoromĆ©thylsulfinylphĆ©nyl)cyanoacĆ©tamide (2,7 g, 59%) sous forme de cristaux incolores: F 164-165Ā°; IR (KBr) 3280, 1678, 1615, 1592, 1550, 1497, 1405, 1348, 1307, 1262, 1195, 1175, 1141, 1085, 1067 ; 1H RMN (D6-DMSO) Ī“ 10,80 (1H, s large), 7,91 (4H, s), 4,03 (2H, s). Ce produit peut ĆŖtre utilisĆ© sans autre purification.A) N- (4'-trifluoromethylthiophenyl) cyanoacetamide (4.35 g, 0.0167 mol) (EP 0484223) in acetic acid (15 ml) was stirred at room temperature overnight with peracetic acid (8.0 ml 32% w / v, 0.035 mol). The mixture was poured onto ice / water and extracted into ethyl acetate. The extracts were washed with an aqueous solution of sodium bicarbonate, dried (MgSO 4 ) and evaporated to give a colorless solid (4.6 g). Chromotography on silica gel (1-10% acetone in dichloromethane) gave N- (4'-trifluoromethylsulfinylphenyl) cyanoacetamide (2.7 g, 59%) in the form of colorless crystals: M 164-165 Ā° ; IR (KBr) 3280, 1678, 1615, 1592, 1550, 1497, 1405, 1348, 1307, 1262, 1195, 1175, 1141, 1085, 1067; 1 H NMR (D 6 -DMSO) Ī“ 10.80 (1H, s broad), 7.91 (4H, s), 4.03 (2H, s). This product can be used without further purification.
  • B) Les fractions rĆ©siduelles (1,7 g) de la chromatographie prĆ©cĆ©dente ont Ć©tĆ© rĆ©unies et dissoutes dans de l'acide acĆ©tique (6 ml) et traitĆ©es avec de l'acide peracĆ©tique (6 ml). Le mĆ©lange a Ć©tĆ© chauffĆ© Ć  50Ā°C pendant une nuit, versĆ© dans de l'eau et extrait dans de l'acĆ©tate d'Ć©thyle. Les extraits ont Ć©tĆ© lavĆ©s par du bicarbonate de sodium aqueux, sĆ©chĆ©s (MgSO4) et Ć©vaporĆ©s. La chromatographie sur gel de silice (100 g) (2-3% d'acĆ©tone dans du dichloromĆ©thane) a donnĆ© le N-(4'-trifluoromĆ©thylsulfonylphĆ©nyl)cyanoacĆ©tamide sous forme de crystaux incolores (1,06 g, 22%) : F 135-137Ā°; IR (KBr) 3343, 3316, 1724, 1608, 1592, 1538, 1409, 1351, 1217, 1199, 1186, 1170, 1147, 1075 ; 1H RMN (D6-DMSO) Ī“ 11,09 (1H, s), 8,15 (2H, d, J = 9), 8,00 (2H, d, J = 9), 4,08 (2H, s). Ce produit peut ĆŖtre utilisĆ© sans autre purification.B) The residual fractions (1.7 g) from the previous chromatography were combined and dissolved in acetic acid (6 ml) and treated with peracetic acid (6 ml). The mixture was heated at 50 Ā° C overnight, poured into water and extracted into ethyl acetate. The extracts were washed with aqueous sodium bicarbonate, dried (MgSO 4 ) and evaporated. Chromatography on silica gel (100 g) (2-3% acetone in dichloromethane) gave N- (4'-trifluoromethylsulfonylphenyl) cyanoacetamide in the form of colorless crystals (1.06 g, 22%): F 135-137 Ā°; IR (KBr) 3343, 3316, 1724, 1608, 1592, 1538, 1409, 1351, 1217, 1199, 1186, 1170, 1147, 1075; 1 H NMR (D 6 -DMSO) Ī“ 11.09 (1H, s), 8.15 (2H, d, J = 9), 8.00 (2H, d, J = 9), 4.08 (2H , s). This product can be used without further purification.

    • Exemple 2 : PrĆ©paration de N-(4'-trifluoromĆ©thylsulfinylphĆ©nyl) 2-cyano-3-cyclopropyl-3-hydroxy-prop-2-Ć©namide Example 2 Preparation of N- (4'-trifluoromethylsulfinylphenyl) 2-cyano-3-cyclopropyl-3-hydroxy-prop-2-enamide

    Le N-(4'-trifluoromĆ©thylsulfinylphĆ©nyl)cyanoacĆ©tamide (3,1 g, 0,0112 mol) dans du THF sec (100 ml) a Ć©tĆ© traitĆ© avec de l'imidazole (10 mg, catalytique) et l'hydrure de sodium (dispersion d'huile Ć  80 %) (0,75 g, 0,0246 mol) et agitĆ© Ć  tempĆ©rature ambiante pendant 90 minutes. Du chlorure de cyclopropylcarbonyle (1,32 ml, 0,0146 mol) a Ć©tĆ© ajoutĆ© goutte Ć  goutte et la solution agitĆ©e Ć  tempĆ©rature ambiante pendant 10 minutes, versĆ©e dans de la glace/HCl 1M et filtrĆ©e. Le produit prĆ©cipitĆ© a Ć©tĆ© rĆ©cupĆ©rĆ© par dispersion, dissous dans du dichloromĆ©thane et passĆ© sur une courte colonne de gel de silice (dichloromĆ©thane) pour donner le N-(4'-trifluoromĆ©thylsulfinylphĆ©nyl)2-cyano-3-cyclopropyl-3-hydroxy-prop-2-Ć©namide (2,54 g, 66%) : F 155-7Ā° ; IR (KBr) 3280, 2219, 1603, 1575, 1536, 1496, 1406, 1353, 1195, 1174, 1141, 1090, 1070, 895 ; 1H RMN (CDCl3) Ī“ 15,49 (1H, s), 7,89 (1H, s), 7,82 (4H, s), 2,18 (1H, m), 1,37 (2H, m), 1,22 (2H, m). Analyse: calculĆ© : C14H11F3N2O3S : C, 48,84, H, 3,22 ; N, 8,13 ; F, 16,55 ; S, 9,31.
    TrouvĆ© : C, 49,03 ; H, 3,29 ; N, 8,17 ; F, 16,39 ; S, 9,35.    N- (4'-trifluoromethylsulfinylphenyl) cyanoacetamide (3.1 g, 0.0112 mol) in dry THF (100 ml) was treated with imidazole (10 mg, catalytic) and sodium hydride ( 80% oil dispersion) (0.75 g, 0.0246 mol) and stirred at room temperature for 90 minutes. Cyclopropylcarbonyl chloride (1.32 ml, 0.0146 mol) was added dropwise and the solution stirred at room temperature for 10 minutes, poured into ice / 1M HCl and filtered. The precipitated product was collected by dispersion, dissolved in dichloromethane and passed over a short column of silica gel (dichloromethane) to give N- (4'-trifluoromethylsulfinylphenyl) 2-cyano-3-cyclopropyl-3-hydroxy-prop -2-enamide (2.54 g, 66%): mp 155-7 Ā°; IR (KBr) 3280, 2219, 1603, 1575, 1536, 1496, 1406, 1353, 1195, 1174, 1141, 1090, 1070, 895; 1 H NMR (CDCl 3 ) Ī“ 15.49 (1H, s), 7.89 (1H, s), 7.82 (4H, s), 2.18 (1H, m), 1.37 (2H, m), 1.22 (2H, m). Analysis: calculated: C 14 H 11 F 3 N 2 O 3 S: C, 48.84, H, 3.22; N, 8.13; F, 16.55; S, 9.31.
    Found: C, 49.03; H, 3.29; N, 8.17; F, 16.39; S, 9.35.

    Exemple 3 : PrƩparation de N-(4'-trifluoromƩthylsulfonylphƩnyl)-2-cyano-3-cyclopropyl-3-hydroxy-prop-2-Ʃnamide Example 3 Preparation of N- (4'-trifluoromethylsulfonylphenyl) -2-cyano-3-cyclopropyl-3-hydroxy-prop-2-enamide

    Le traitement de N-(4'-trifluoromĆ©thylsulfonylphĆ©nyl)cyanoacĆ©tamide par la mĆ©thode ci-dessus a donnĆ© le N-(4'-trifluoromĆ©thylsulfinylphĆ©nyl)2-cyano-3-cyclopropyl-3-hydroxy-prop-2-Ć©namide (65%) : F 168-170Ā° ; IR (KBr) 3300, 2218, 1638, 1579, 1529, 1499, 1411, 1363, 1349, 1322, 1268, 1247, 1216, 1190, 1177, 1142, 1079, 986, 894, 841 ; 1H RMN (CDCl3) Ī“ 15,30 (1H, s), 8,03 (2H, d, J = 8,8), 7,92 (1H, s), 7,85 (2H, d, J = 8,8), 2,18 (1H, m), 1,41 (2H, m), 1,25 (2H, m). Analyse: calculĆ© : C14H11F3N2O4S : C, 46,67 ; H, 3,08 ; F, 15,82 ; N, 7,77 ; S, 8,90. TrouvĆ© : C, 47,01 ; H, 3,17 ; F, 15,57, N, 7,84 ; S, 8,79.Treatment of N- (4'-trifluoromethylsulfonylphenyl) cyanoacetamide by the above method gave N- (4'-trifluoromethylsulfinylphenyl) 2-cyano-3-cyclopropyl-3-hydroxy-prop-2-enamide (65%) : M 168-170 Ā°; IR (KBr) 3300, 2218, 1638, 1579, 1529, 1499, 1411, 1363, 1349, 1322, 1268, 1247, 1216, 1190, 1177, 1142, 1079, 986, 894, 841; 1 H NMR (CDCl 3 ) Ī“ 15.30 (1H, s), 8.03 (2H, d, J = 8.8), 7.92 (1H, s), 7.85 (2H, d, J = 8.8), 2.18 (1H, m), 1.41 (2H, m), 1.25 (2H, m). Analysis: calculated: C 14 H 11 F 3 N 2 O 4 S: C, 46.67; H, 3.08; F, 15.82; N, 7.77; S, 8.90. Found: C, 47.01; H, 3.17; F, 15.57, N, 7.84; S, 8.79.

    Exemple 4 : Dosage de la dihydro-orotate dƩshydrogƩnase (DHO-DH) EXAMPLE 4 Determination of Dihydro-Orotate Dehydrogenase (DHO-DH)

    La transformation de dihydro-orotate en orotate catalysƩe par la DHO-DH de la membrane de rate humaine est rƩalisƩe par la rƩduction de la coenzyme Q10. La rƩoxydation de la coenzyme Q10 est liƩe Ơ la rƩduction du dichlorophƩnolindophƩnol et elle est suivie par la perte d'absorbance Ơ 650 nm. La vitesse de perte d'absorbance est une mesure directe de la rƩaction catalysƩe par l'enzyme DHO-DH. Les vitesses de rƩaction ont ƩtƩ mesurƩes en prƩsence d'une gamme de concentrations du composƩ Ơ tester et on a dƩterminƩ Ơ l'aide des graphiques la concentration donnant 50% d'inhibition (CI50) (voir Williamson et al. (1995), "Dihydroorotate dehydrogenase, a high affinity binding protein for A77 1726 and mediator of a range of the biological effects of the immunomodulatory compounds" [La dihydro-orotate dƩshydrogƩnase, une protƩine de liaison Ơ haute affinitƩ pour A77 1726 et mƩdiatrice d'une gamme d'effets biologiques des composƩs immunomodulateurs], The Journal of Biological Chemistry).The transformation of dihydro-orotate into orotate catalyzed by DHO-DH of the human spleen membrane is carried out by the reduction of coenzyme Q 10 . The reoxidation of coenzyme Q 10 is linked to the reduction of dichlorophenolindophenol and is followed by the loss of absorbance at 650 nm. The rate of loss of absorbance is a direct measure of the reaction catalyzed by the enzyme DHO-DH. The reaction rates were measured in the presence of a range of concentrations of the test compound and the concentration giving 50% inhibition (IC 50 ) was determined using the graphs (see Williamson et al. (1995) , "Dihydroorotate dehydrogenase, a high affinity binding protein for A77 1726 and mediator of a range of the biological effects of the immunomodulatory compounds" [Dihydroorotate dehydrogenase, a high affinity binding protein for A77 1726 and mediator of a range of biological effects of immunomodulatory compounds], The Journal of Biological Chemistry).

    PrƩparation de membranes de rate humainePreparation of human spleen membranes

    Des prĆ©parations de membranes brutes ont Ć©tĆ© rĆ©alisĆ©es en utilisant une modification d'un protocole de centrifugation diffĆ©rentielle publiĆ©. Tous les protocoles ont Ć©tĆ© effectuĆ©s dans de la glace ou Ć  une tempĆ©rature de 4Ā°C en utilisant des appareils et des tampons prĆ©-refroidis.Raw membrane preparations were made using a modification of a centrifugation protocol differential published. All protocols have been performed in ice or at a temperature of 4 Ā° C in using pre-cooled devices and pads.

    Le tissu splĆ©nique a Ć©tĆ© dĆ©coupĆ©, puis homogĆ©nĆ©isĆ© avec un homogĆ©nĆ©isateur en verre Ć  tĆ©flon (environ 10 passages Ć  250 t/min) dans 10 volumes de tampons d'homogĆ©nĆ©isation (10 mM de Tris-HCl contenant 0,25 M de saccharose, 10 Āµg/ml d'inhibiteur de trypsine de soja, 2 Āµg/ml d'aprotinine, de la pepstatine A et de la leupeptine pH 7,4. L'homogĆ©nat a Ć©tĆ© centrifugĆ© Ć  ā‰ˆ470 g pendant 10 minutes et le surnageant prĆ©servĆ©. Les culots ont Ć©tĆ© rĆ©mis en suspension dans 4-6 volumes de tampon d'homogĆ©nĆ©isation en utilisant 5 passages de l'homogĆ©nĆ©isateur en verre Ć  tĆ©flon (250 t/min) et centrifugĆ©s pendant 10 minutes Ć  ā‰ˆ470 g. Le surnageant a Ć©tĆ© rĆ©uni avec celui provenant de la premiĆØre Ć©tape de centrifugation (fraction post-nuclĆ©aire); les culots contenant les noyaux et les dĆ©bris des tissus ont Ć©tĆ© jetĆ©s. Le surnageant post-nuclĆ©aire a Ć©tĆ© centrifugĆ© Ć  125000 g pendant 40 minutes. Les culots ont Ć©tĆ© remis en suspension dans du tampon d'homogĆ©nĆ©isation (2 ml/g de tissu humide) en utilisant environ 10 passages de l'homogĆ©nĆ©isateur en verre Ć  tĆ©flon. Des aliquotes de la prĆ©paration ont Ć©tĆ© conservĆ©s Ć  -80Ā°C. Les membranes n'ont pas Ć©tĆ© rĆ©congĆ©lĆ©es une fois dĆ©congĆ©lĆ©es (voir Ozols J. "Preparation of Membrane Fractions" [PrĆ©paration de Fractions Membranaires], dans : Methods in Enzymology Volume 182, Guide to Protein Purification (Ed. Deutscher MP), pp 225-235. Academic Press, London, 1990).The splenic tissue was cut, then homogenized with a Teflon glass homogenizer (approximately 10 passages 250 rpm) in 10 volumes of homogenization buffers (10 mM Tris-HCl containing 0.25 M sucrose, 10 Āµg / ml soybean trypsin inhibitor, 2 Āµg / ml aprotinin, pepstatin A and leupeptin pH 7.4. The homogenate was centrifuged at ā‰ˆ470 g for 10 minutes and the supernatant preserved. The pellets were resuspended in 4-6 volumes of homogenization buffer using 5 passages of the Teflon glass homogenizer (250 rpm) and centrifuged for 10 minutes at ā‰ˆ470 g. The supernatant has been collected with that from the first centrifugation step (post-nuclear fraction); the pellets containing the nuclei and tissue debris was discarded. The post-nuclear supernatant was centrifuged at 125,000 xg for 40 minutes. The pellets were resuspended in homogenization buffer (2 ml / g of wet tissue) using approximately 10 passages of the homogenizer in Teflon glass. Aliquots of the preparation were stored at -80 Ā° C. Membranes have not been re-frozen once thawed (see Ozols J. "Preparation of Membrane Fractions" Membrane Fractions], in: Methods in Enzymology Volume 182, Guide to Protein Purification (Ed. Deutscher MP), pp 225-235. Academic Press, London, 1990).

    L'inhibition de l'activitĆ© de la dihydro-orotate dĆ©shydrogĆ©nase de la rate humaine par cinq composĆ©s Ć  tester a Ć©tĆ© Ć©valuĆ©e en utilisant un dosage liĆ© au DCIP (voir Lakaschus, G., and Loffler, M. (1992) Biochem. Pharmacol. 43, 1025-1030). Des membranes (0,33-0,5 mg de protĆ©ine) ont Ć©tĆ© incubĆ©es avec 100 ĀµM de coenzyme Q10 dans 50 mM de Tris-HCl, 0,1% de Triton X-100, 1 mM de KCN, pH 8,0. AprĆØs une prĆ©-incubation de 90 minutes Ć  37Ā°C, la rĆ©action a Ć©tĆ© initiĆ©e par l'addition de 500 ĀµM de dihydro-orotate et la rĆ©duction de DCIP (200 ĀµM) a Ć©tĆ© suivie par la perte d'absorbance Ć  650 nm en utilisant un lecteur de plaque Ć  96 puits, Ć  37Ā°C. Les concentrations de mĆ©dicaments ont Ć©tĆ© augmentĆ©es Ć  des intervalles d'une demi-unitĆ© log ou d'une unitĆ© log entiĆØre, chaque concentration Ć©tant testĆ©e au moins en triple.The inhibition of the dihydro-orotate dehydrogenase activity of the human spleen by five test compounds was evaluated using an assay linked to DCIP (see Lakaschus, G., and Loffler, M. (1992) Biochem. Pharmacol . 43, 1025-1030). Membranes (0.33-0.5 mg of protein) were incubated with 100 Ī¼M of coenzyme Q 10 in 50 mM of Tris-HCl, 0.1% of Triton X-100, 1 mM of KCN, pH 8, 0. After a 90-minute pre-incubation at 37 Ā° C, the reaction was initiated by the addition of 500 ĀµM dihydro-orotate and the reduction in DCIP (200 ĀµM) was followed by the loss of absorbance at 650 nm using a 96-well plate reader at 37 Ā° C. Drug concentrations were increased at intervals of half a log unit or an entire log unit, each concentration being tested at least in triplicate.

    RĆ©sultatsResults

    Les rƩsultats suivants ont ƩtƩ trouvƩs pour trois composƩs de l'art intƩrieur (A, B, C) et pour les composƩs des exemples 3 et 2 dans le test de l'inhibition de l'enzyme DHO-DH humaine :

    Figure 00110001
    The following results were found for three internal art compounds (A, B, C) and for the compounds of Examples 3 and 2 in the test for the inhibition of the human DHO-DH enzyme:
    Figure 00110001

    Claims (12)

    1. Compounds of formula (I) :
      Figure 00190001
      in which
      R1
      represents a cyclopropyl group or a -CH2-CH = CH2 group;
      R2
      represents a -S(O)n-(CF2)x-CF3 group, in which
      n
      designates 1 or 2, x designates zero or 1;
      R3
      represents a hydrogen atom or an alkyl radical containing 1 to 3 carbon atoms;
      m
      designates zero or 1;
      as well as their pharmaceutically acceptable salts.
    2. Compounds according to claim 1, characterized in that R1 represents a cyclopropyl group, and R2, R3 and m are as defined in claim 1.
    3. Compounds according to claim 1 or claim 2, characterized in that R3 represents a hydrogen atom or a methyl group and R1, R2 and m are as defined in claim 1 or claim 2.
    4. Compound according to any one of claims 1 to 3, chosen from:
      N-(4'-trifluoromethylsulphinylphenyl)2-cyano-3-cyclopropyl-3-hydroxy-prop-2-enamide and
      N-(4'-trifluoromethylsulphonylphenyl)2-cyano-3-cyclopropyl-3-hydroxy-prop-2-enamide and their pharmaceutically acceptable salts.
    5. Preparation process for a compound of formula I as defined in claim 1, comprising the reaction of a compound of formula (IV)
      Figure 00190002
      in which R2, R3, m, n and x are as defined above, successively with a base, if appropriate in the presence of a catalyst such as imidazole, then with a compound of formula (V) X-CO-R1 in which X represents a labile group, for example a halogen atom, and R1 is as defined above.
    6. Process according to claim 5, characterized in that the compounds of formula 4 as defined in claim 5 are prepared by oxidation at the level of the sulphur atom of a compound of formula (IVa)
      Figure 00200001
      in which R'2 designates an -S-(CF2)x-CF3 group and R3, x and m are as defined in claim 1.
    7. Process according to claim 6, characterized in that the compounds of formula (IVa) as defined in claim 6 are prepared by reacting a compound of formula (IIa)
      Figure 00200002
      in which R'2, x, R3 and m are as defined in claim 1, with a compound of formula III or a functional derivative of this
      Figure 00200003
    8. Process according to claim 5, characterized in that the compounds of formula (IV) as defined in claim 5 are prepared by the oxidation of the sulphur atom of compounds of formula (IIa) as defined in claim 7, then reacting the product with a compound of formula (III) as defined in claim 7 or a functional derivative of this.
    9. Compounds of formula IV
      Figure 00210001
      in which
      R2 represents an -S(O)n-(CF2)x-CF3 group in which n designates 1 or 2 and x is zero or 1;
      R3 represents a hydrogen atom or an alkyl radical containing 1 to 3 carbon atoms; and m designates zero or 1.
    10. Pharmacological composition comprising at least one compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable base addition salt of this combined with one or more pharmacologically acceptable diluents, supports and/or excipients as an active ingredient.
    11. Compound of formula (I) as defined in claim 1 or a pharmacologically acceptable base addition salt of this intended to be used as a medicament.
    12. Compound of formula (I) as defined in claim 1 or a pharmacologically acceptable base addition salt of this intended to be used in the treatment of rheumatoid polyarthritis, chronic inflammatory diseases of immunological or non-immunological origin, or cancer.
    EP96402091A 1995-10-02 1996-10-01 Trifluoromethylsulfonylphenyl or trifluoromethylsulfinylphenyl group containing 2-cyano-3-hydroxy-propenamide derivatives, process for their preparation, their use as medicaments and pharmaceutical compositions containing them Expired - Lifetime EP0767167B1 (en)

    Applications Claiming Priority (2)

    Application Number Priority Date Filing Date Title
    GB9520092 1995-10-02
    GBGB9520092.9A GB9520092D0 (en) 1995-10-02 1995-10-02 Chemical compounds

    Publications (2)

    Publication Number Publication Date
    EP0767167A1 EP0767167A1 (en) 1997-04-09
    EP0767167B1 true EP0767167B1 (en) 2000-02-16

    Family

    ID=10781638

    Family Applications (1)

    Application Number Title Priority Date Filing Date
    EP96402091A Expired - Lifetime EP0767167B1 (en) 1995-10-02 1996-10-01 Trifluoromethylsulfonylphenyl or trifluoromethylsulfinylphenyl group containing 2-cyano-3-hydroxy-propenamide derivatives, process for their preparation, their use as medicaments and pharmaceutical compositions containing them

    Country Status (10)

    Country Link
    US (1) US5693844A (en)
    EP (1) EP0767167B1 (en)
    JP (1) JPH09132559A (en)
    AT (1) ATE189810T1 (en)
    DE (1) DE69606677T2 (en)
    DK (1) DK0767167T3 (en)
    ES (1) ES2143159T3 (en)
    GB (1) GB9520092D0 (en)
    GR (1) GR3033175T3 (en)
    PT (1) PT767167E (en)

    Families Citing this family (4)

    * Cited by examiner, ā€  Cited by third party
    Publication number Priority date Publication date Assignee Title
    RU2001106631A (en) 1998-09-11 2004-03-20 ŠŠ“Š·ŠøŠ½Š¾Š¼Š¾Ń‚Š¾ ŠšŠ¾., Š˜Š½Šŗ. (Jp) DERIVATIVES OF BENZENE AND THEIR PHARMACEUTICAL USE
    US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
    US20140031383A1 (en) 2011-02-08 2014-01-30 Dana-Farber Cancer Institute, Inc. Methods for treatment of melanoma
    CN105916522A (en) 2013-11-22 2016-08-31 å»ŗę–°å…¬åø Novel methods for treating neurodegenerative diseases

    Family Cites Families (9)

    * Cited by examiner, ā€  Cited by third party
    Publication number Priority date Publication date Assignee Title
    IT1116382B (en) * 1977-11-30 1986-02-10 Sigma Tau Ind Farmaceuti INDUSTRIAL PREPARATION METHOD FOR ISOBUTYRIC RS-BETA-BENZOYLAMINE ACID
    IT1097280B (en) * 1978-06-26 1985-08-31 Montedison Spa BISMETINIC PIGMENTS
    US4710514A (en) * 1982-05-04 1987-12-01 Sumitomo Chemical Company, Limited Fungicidal carbamates and thiolcarbamates
    US4946867A (en) * 1987-09-07 1990-08-07 Sumitomo Chemical Company, Limited Cyanoacetamide derivative, and plant disease protectant comprising the same as an active ingredient
    DK0527736T3 (en) * 1990-05-18 1997-10-20 Hoechst Ag Isoxazole-4-carboxylic acid amides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and the use of these drugs.
    IL99811A (en) * 1990-10-30 1996-03-31 Roussel Uclaf 3-cycloalkyl-propanamides their tautomer forms and their salts preparation process and compositions containing them
    IL102790A (en) * 1991-09-17 1996-01-31 Roussel Uclaf 3-Cycloalkyl-prop-2- enamide derivatives
    GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
    GB9313365D0 (en) * 1993-06-29 1993-08-11 Roussel Lab Ltd Chemical compounds

    Also Published As

    Publication number Publication date
    DK0767167T3 (en) 2000-07-24
    DE69606677D1 (en) 2000-03-23
    PT767167E (en) 2000-06-30
    EP0767167A1 (en) 1997-04-09
    US5693844A (en) 1997-12-02
    GR3033175T3 (en) 2000-08-31
    JPH09132559A (en) 1997-05-20
    DE69606677T2 (en) 2000-08-17
    ATE189810T1 (en) 2000-03-15
    GB9520092D0 (en) 1995-12-06
    ES2143159T3 (en) 2000-05-01

    Similar Documents

    Publication Publication Date Title
    EP0283390B1 (en) Thiazole derivatives active on the cholinergic system, process for their preparation and pharmaceutical compositions containing them
    EP0281459A1 (en) Dextrorotatory enantiomer of alpha-(4,5,6,7-tetrahydrothieno[3,2-c]pyrid-5-yl)(2-chlorophenyl)methyl acetate, process for its preparation and pharmaceutical compositions containing it
    JP2572115B2 (en) 5-amino or substituted amino-1,2,3-triazoles useful as antiproliferative agents
    EP0421861A1 (en) 2-Hydroxy thiophene- and furan derivatives condensed with a nitrogen containing ring, process for their preparation and their therapeutical application
    EP0370901A1 (en) Central nervous system active chromane derivatives, process for their preparation and pharmaceutical compositions containing them
    EP0684241A1 (en) N-pyridyl carboxamide derivatives, processes for their preparation and pharmaceutical compositions containing them
    CA3105662A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
    JP2001525408A (en) S-oxide and S, S-dioxidetetrahydrothiopyran phenyloxazolidinone
    EP0767167B1 (en) Trifluoromethylsulfonylphenyl or trifluoromethylsulfinylphenyl group containing 2-cyano-3-hydroxy-propenamide derivatives, process for their preparation, their use as medicaments and pharmaceutical compositions containing them
    EP0117771B1 (en) Imino-2 pyrrolidines, process for their preparation and their therapeutical use
    EP0573318A1 (en) Phenyl carboxamide isoxazole derivatives and salts, process for their preparation and the new intermediates thereof. Their use as pharmaceuticals and pharmaceutical compositions containing them
    FR2567887A1 (en) NEW SUBSTITUTED AMIDES, THEIR PREPARATION AND THE MEDICINES THAT CONTAIN THEM
    WO1998057928A1 (en) Elevation of hdl cholesterol by 2-(4-chloro -1-aryl-butylidene) -hydrazinecarbothioamides
    KR20010040681A (en) PDE IV inhibiting pyridine derivatives
    US6008362A (en) Elevation of HDL cholesterol by 2-(-4-chlorol-1-aryl-butylidene)-hydrazinecarbothioamides
    EP0015214A1 (en) Derivatives of substituted 2-benzoyl glycinanilides, their preparation and their use in anxiolytic medicaments
    BE898151A (en) New quinazoline derivatives, their preparation and their use as drugs.
    FR2491064A1 (en) QUINOLONES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITION CONTAINING SAME
    EP1215213A2 (en) Bicyclic amino-pyrazone derivatives, their preparation and pharmaceutical compositions containing them
    CA2166032A1 (en) 1-oxo-2-(phenylsulfonylamino)pentylpiperidine; process for preparing them and their use as therapeutic agents
    JPH0641068A (en) Indoline derivative and composition for treating allergic and inflammatory diseases
    JPS62153285A (en) Supression of 5-lipoxigenase route
    FR2675144A1 (en) NOVEL DIFLUOREOUS QUINOLONES - THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
    EP0168309B1 (en) Isoxazoloquinolinone derivatives, process and intermediates for their preparation, use as medicaments and compositions containing them
    EP0027412A1 (en) Pyridine derivatives, process for their preparation and medicaments containing them

    Legal Events

    Date Code Title Description
    PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

    Free format text: ORIGINAL CODE: 0009012

    AK Designated contracting states

    Kind code of ref document: A1

    Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

    RIN1 Information on inventor provided before grant (corrected)

    Inventor name: WILLIAMSON, RICHARD ALEXANDER

    Inventor name: KUO, ELIZABERT ANNE

    Inventor name: KAY, DAVID PAUL

    17P Request for examination filed

    Effective date: 19971009

    RAP1 Party data changed (applicant data changed or rights of an application transferred)

    Owner name: HOECHST MARION ROUSSEL

    GRAG Despatch of communication of intention to grant

    Free format text: ORIGINAL CODE: EPIDOS AGRA

    17Q First examination report despatched

    Effective date: 19990511

    GRAG Despatch of communication of intention to grant

    Free format text: ORIGINAL CODE: EPIDOS AGRA

    GRAH Despatch of communication of intention to grant a patent

    Free format text: ORIGINAL CODE: EPIDOS IGRA

    GRAH Despatch of communication of intention to grant a patent

    Free format text: ORIGINAL CODE: EPIDOS IGRA

    GRAA (expected) grant

    Free format text: ORIGINAL CODE: 0009210

    AK Designated contracting states

    Kind code of ref document: B1

    Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

    REF Corresponds to:

    Ref document number: 189810

    Country of ref document: AT

    Date of ref document: 20000315

    Kind code of ref document: T

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: EP

    ITF It: translation for a ep patent filed
    REF Corresponds to:

    Ref document number: 69606677

    Country of ref document: DE

    Date of ref document: 20000323

    GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

    Effective date: 20000404

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: NV

    Representative=s name: A. BRAUN, BRAUN, HERITIER, ESCHMANN AG PATENTANWAE

    REG Reference to a national code

    Ref country code: ES

    Ref legal event code: FG2A

    Ref document number: 2143159

    Country of ref document: ES

    Kind code of ref document: T3

    REG Reference to a national code

    Ref country code: IE

    Ref legal event code: FG4D

    Free format text: FRENCH

    REG Reference to a national code

    Ref country code: PT

    Ref legal event code: SC4A

    Free format text: AVAILABILITY OF NATIONAL TRANSLATION

    Effective date: 20000411

    EN Fr: translation not filed
    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: FR

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20000713

    REG Reference to a national code

    Ref country code: DK

    Ref legal event code: T3

    EN4 Fr: notification of non filing translation in an earlier bopi is erroneous
    PLBE No opposition filed within time limit

    Free format text: ORIGINAL CODE: 0009261

    STAA Information on the status of an ep patent application or granted ep patent

    Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

    26N No opposition filed
    REG Reference to a national code

    Ref country code: FR

    Ref legal event code: TP

    REG Reference to a national code

    Ref country code: GB

    Ref legal event code: IF02

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: LU

    Payment date: 20020802

    Year of fee payment: 7

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: PT

    Payment date: 20020805

    Year of fee payment: 7

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: SE

    Payment date: 20020808

    Year of fee payment: 7

    Ref country code: BE

    Payment date: 20020808

    Year of fee payment: 7

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: FI

    Payment date: 20020906

    Year of fee payment: 7

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: IE

    Payment date: 20020917

    Year of fee payment: 7

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: GB

    Payment date: 20020926

    Year of fee payment: 7

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: ES

    Payment date: 20020927

    Year of fee payment: 7

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: CH

    Payment date: 20021023

    Year of fee payment: 7

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: GR

    Payment date: 20021024

    Year of fee payment: 7

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: DK

    Payment date: 20021029

    Year of fee payment: 7

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: AT

    Payment date: 20021030

    Year of fee payment: 7

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: FR

    Payment date: 20021031

    Year of fee payment: 7

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: PFA

    Free format text: HOECHST MARION ROUSSEL TRANSFER- AVENTIS PHARMA S.A.

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: NL

    Payment date: 20021130

    Year of fee payment: 7

    REG Reference to a national code

    Ref country code: GB

    Ref legal event code: 732E

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: DE

    Payment date: 20021227

    Year of fee payment: 7

    NLS Nl: assignments of ep-patents

    Owner name: AVENTIS PHARMA S.A.

    REG Reference to a national code

    Ref country code: PT

    Ref legal event code: PC4A

    Free format text: AVENTIS PHARMA, S.A. FR

    Effective date: 20030110

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: LU

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20031001

    Ref country code: IE

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20031001

    Ref country code: GB

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20031001

    Ref country code: FI

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20031001

    Ref country code: AT

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20031001

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: SE

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20031002

    Ref country code: ES

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20031002

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: LI

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20031031

    Ref country code: DK

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20031031

    Ref country code: CH

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20031031

    Ref country code: BE

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20031031

    BERE Be: lapsed

    Owner name: S.A. *AVENTIS PHARMA

    Effective date: 20031031

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: PT

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20040430

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: NL

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20040501

    Ref country code: DE

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20040501

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: GR

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20040504

    GBPC Gb: european patent ceased through non-payment of renewal fee

    Effective date: 20031001

    EUG Se: european patent has lapsed
    REG Reference to a national code

    Ref country code: DK

    Ref legal event code: EBP

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: PL

    NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

    Effective date: 20040501

    REG Reference to a national code

    Ref country code: IE

    Ref legal event code: MM4A

    REG Reference to a national code

    Ref country code: FR

    Ref legal event code: ST

    Ref country code: PT

    Ref legal event code: MM4A

    Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

    Effective date: 20040430

    REG Reference to a national code

    Ref country code: ES

    Ref legal event code: FD2A

    Effective date: 20031002

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: IT

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20051001